Heart failure therapy based on interventricular mechanics and cardio-vascular communications

Schranz, Dietmar; Akintuerk, Hakan; Esmaeili, Anoosh; Latus, Heiner; Apitz, Christian

doi:10.21037/cdt-20-347

Cited by 5 publications

(3 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HF is a complex interplay of neuro-hormonal, molecular-cellular, and circulatory hemodynamic factors rather than a simple dysfunction of the heart ( 29 , 30 ). Although the majority of CHD is based on a variety of factors, some cases, such as specific cardiomyopathies, are only associated with a chromosomal abnormality, a single gene defect, teratogens, or maternal metabolic syndrome.…”

Section: Pathophysiology Of Pediatric Congenital Hfmentioning

confidence: 99%

Insights and perspectives into clinical biomarker discovery in pediatric heart failure and congenital heart disease—a narrative review

Liem¹,

Cadeiras²,

Setty³

2023

Cardiovasc Diagn Ther

View full text Add to dashboard Cite

Background and Objective: Heart failure (HF) in the pediatric population is a multi-factorial process with a wide spectrum of etiologies and clinical manifestations, that are distinct from the adult HF population, with congenital heart disease (CHD) as the most common cause. CHD has high morbidity/mortality with nearly 60% developing HF during the first 12 months of life. Hence, early discovery and diagnosis of CHD in neonates is pivotal. Plasma B-type natriuretic peptide (BNP) is an increasingly popular clinical marker in pediatric HF, however, in contrast to adult HF, it is not yet included in pediatric HF guidelines and there is no standardized reference cut-off value. We explore the current trends and prospects of biomarkers in pediatric HF, including CHD that can aid in diagnosis and management.Methods: As a narrative review, we will analyze biomarkers with respect to diagnosis and monitoring in specific anatomical types of CHD in the pediatric population considering all English PubMed publications till June 2022.

show abstract

Section: Pathophysiology Of Pediatric Congenital Hfmentioning

confidence: 99%

Insights and perspectives into clinical biomarker discovery in pediatric heart failure and congenital heart disease—a narrative review

Liem¹,

Cadeiras²,

Setty³

2023

Cardiovasc Diagn Ther

View full text Add to dashboard Cite

show abstract

“… 3–5 With the advent of technology and medical advancements, pharmacological agents and non-pharmacological agents such as the implantation of intra-cardiac defibrillators (ICD) and cardiac resynchronization therapy have markedly improved clinical outcomes of patients with CHF. 6–9 However, CHF remains associated with high mortality rates, high hospitalization rates and poor quality of life outcomes. 1 …”

Section: Introductionmentioning

confidence: 99%

Behavioral Interventions for the Patient–Caregiver Unit in Patients with Chronic Heart Failure: A Systematic Review of Caregiver Outcomes

Suthershinii¹,

Amanda²,

Lee³

et al. 2022

JMDH

View full text Add to dashboard Cite

“…Perhaps the most innovative approach in pediatric PH in the last decade was the renaissance of the Potts shunt as a procedure to treat children with severe PAH and systemic or suprasystemic RV pressures and imminent RV failure. Schranz et al present in this series an impressive pathophysiological view on new interventional and surgical approaches to treat children with PH and heart failure (11).…”

mentioning

confidence: 98%

Pediatric pulmonary hypertension

Apitz¹,

Lammers²

2021

Cardiovasc Diagn Ther

Self Cite

View full text Add to dashboard Cite

Pulmonary hypertension (PH) is a life-threatening disease and is characterized by pathological elevation of pulmonary pressure and associated with a heterogeneous spectrum of diseases affecting the pulmonary vasculature (1).The care of patients with PH is a medical specialty in constant flux and shifting paradigms. There are new drugs, changing treatment strategies, renaissance of already almost forgotten surgical techniques like the Potts' shunt and last but not least improved outcome after lung transplantation as last resource for these patients.Despite all available guidelines and recommendations, counselling remains challenging and often has to be patient tailored.Although available treatment options have transformed the outcome of these patients, there is still a long way to go. In this series, we focus on PH in children. While pathobiology and clinical features share similarities in children and adults, pediatric PH provides many differences to adult disease, which need to be considered to provide best possible care for this challenging patient population (Figure 1).The idea for this special series came from a very successful symposium on Pediatric Pulmonary Hypertension which took place in Münster in 2019 organized by Dr. Astrid Lammers in her role as head of the German Working Group of Pediatric Pulmonary Hypertension. Most of the invited speakers, all of them well-known experts in this field, were happy to accept our invitation to write an updated manuscript of their talks. And so, we are now proud to present this special series with the great support of the Editors of CDT.We open with a tribute to Sheila Glennis Haworth, who sadly died in 2020. She actively contributed to our symposium in Münster by giving us the honor presenting the opening lecture on "Lung development and pathogenesis of pulmonary vascular disease". She has been a true pioneer, has participated in the last important decades with more upcoming targeted therapies and she drove clinical and basic research in the field of PH to strive for optimal patient care. Moreover, she has been a passionate medical professional and a true friend to many of us. Therefore, we would like to dedicate this special series to her memory (Appendix 1).The series starts with a commentary from Lammers and Apitz on the new PH definition and its impact on pediatric PH. According to international guidelines, PH used to be defined as elevation of the mean pulmonary arterial pressure (mPAP) ≥25 mmHg. During the 6th World Symposium on PH in 2018, a revised hemodynamic definition of PH was proposed, lowering the threshold from ≥25 mmHg to >20 mmHg (2). This new definition has also been accepted by the Pediatric Task Force of the World Symposium to establish a uniform language and facilitate transition to adult services (3). This decision resulted in controversial debates within the expert community as the new definition may lead to overdiagnosis and overtreatment of PH. Therefore, a critical expert discussion on the impact of the new PH definition in pediatric PH is p...

show abstract

Heart failure therapy based on interventricular mechanics and cardio-vascular communications

Cited by 5 publications

References 48 publications

Insights and perspectives into clinical biomarker discovery in pediatric heart failure and congenital heart disease—a narrative review

Insights and perspectives into clinical biomarker discovery in pediatric heart failure and congenital heart disease—a narrative review

Behavioral Interventions for the Patient–Caregiver Unit in Patients with Chronic Heart Failure: A Systematic Review of Caregiver Outcomes

Pediatric pulmonary hypertension

Contact Info

Product

Resources

About